When did cytokinetics go public?
Cytokinetics, Incorporated officially completed its initial public offering and began trading its common stock on the NASDAQ stock exchange under the ticker symbol CYTK on April 29, 2004. The late-stage biopharmaceutical enterprise raised vital capital from its public market debut to advance its pioneering muscle biology research and clinical-stage drug candidates targeting severe cardiovascular and neuromuscular diseases.
Related FAQs
Aficamten (marketed under brand names such as Myqorzo) has been authorized as a once-daily oral cardiac myosin inhibitor designed to treat symptomatic obstructive hypertrophic cardiomyopathy.
Wall Street equity research analysts covering Cytokinetics, Incorporated (CYTK) establish a consensus 12-month average price target of approximately $99.37 to $105.00 per share.
Cytokinetics, Incorporated (NASDAQ: CYTK) trades at $76.45 per share, supported by a robust market capitalization exceeding $10.3 billion.
Cytokinetics is a specialty cardiovascular biopharmaceutical company focused on pioneering scientific innovations in muscle biology and developing potential new medicines for patients suffering from diseases of cardiac muscle dysfunction.
Assessing whether Celsius Holdings shares are undervalued requires analyzing standard valuation multiples—such as price-to-earnings and price-to-sales ratios—relative to its historical growth rates and projected future earnings.
Securities or corporate entities trading under ticker abbreviations similar to CELC are evaluated by financial professionals on a case-by-case basis depending on their specific industry sector, such as biotechnology or specialized technology.
Cytokinetics is a late-stage biopharmaceutical enterprise dedicated to discovering, developing, and commercializing muscle biology-directed medicines for treating serious cardiovascular and neuromuscular diseases.
Analyst sentiment for Cytokinetics (CYTK) is overwhelmingly positive, with a consensus rating of "Buy" or "Strong Buy" among market professionals as of mid-2026.
No, Cytokinetics (CYTK) does not pay dividends. As a growth-focused biotechnology company, it prioritizes the reinvestment of all available capital into its research, development, and commercialization efforts.
Cytokinetics is widely considered a promising player in the biotechnology sector, garnering strong positive sentiment from market analysts who view its future prospects favorably.
Market analyst consensus ratings for Tetra Tech, trading under the ticker symbol TTEK, generally feature favorable buy or hold recommendations as equity researchers evaluate robust demand for environmental engineering, water management, and sustai...
Diodes Incorporated records annual revenues scaling between USD 1.3 billion and USD 1.6 billion, positioning the company as a leading global manufacturer and supplier of high-quality discrete, analog, and semiconductor products.
Cytokinetics has developed key cardiovascular drug candidates, notably aficamten (marketed under the brand name MYQORZO), which is a cardiac myosin inhibitor designed for the treatment of adults with symptomatic obstructive hypertrophic cardiomyop...
The stock ticker symbol CYTK represents shares of Cytokinetics, Incorporated, which is a publicly traded biopharmaceutical enterprise listed on the Nasdaq stock exchange.
Dacotah Bank is an established regional financial institution headquartered in Aberdeen, South Dakota, maintaining total consolidated assets exceeding $3.1 billion.